FDA-Approved Medications to Treat Tardive Dyskinesia

Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Learn more from Dr. Joseph McEvoy.

Abstract

Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.

From the Series: Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia

To cite: McEvoy JP. FDA-Approved Medications to Treat Tardive Dyskinesia. J Clin Psychiatry 2020;81(1):NU18041BR3C.

To share: https://doi.org/10.4088/JCP.NU18041BR3C

© Copyright 2019 Physicians Postgraduate Press, Inc.

Target Audience

  • Psychiatrists, Neurologists, NPs/PAs

Learning Objectives

After completing this educational activity, you should be able to:

  • Select FDA-approved medication to treat TD symptoms, considering research on longer-term efficacy and safety
Activity summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Activity opens: 
11/14/2019
Activity expires: 
11/30/2021
Cost:
$0.00
Rating: 
0

SUPPORT STATEMENT

Supported by an educational grant from Neurocrine Biosciences, Inc.

LEARNING OBJECTIVE

After completing this educational activity, you should be able to:

  • Select FDA-approved medication to treat TD symptoms, considering research on longer-term efficacy and safety.

RELEASE, REVIEW, AND EXPIRATION DATES

This brief report activity was published in November 2019 and is eligible for AMA PRA Category 1 Credit™ through November 30, 2021. The latest review of this material was September 2019.

STATEMENT OF NEED AND PURPOSE

Because some clinicians underestimate the risk of TD, especially with newer antipsychotics, they do not advise patients and caregivers of the risk of TD or educate them about early signs to watch for and report. A substantial proportion of patients with TD do not have a timely diagnosis. Clinicians may not recognize early TD symptoms, as mild cases may be more easily missed. Due to TD movements, patients may stop taking their treatments for mood disorders or schizophrenia. Clinicians may inaccurately rate how bothersome side effects are to patients. New medications for TD are available, and evidence-based treatment recommendations have been published. Recent research has explored longer-term safety and efficacy with newer medications. Clinicians need up-to-date guidance on the prevalence of TD, risk factors for TD, recognition of early signs and symptoms of TD, and assessment tools that will help them diagnose and monitor TD. They also need education about discussing TD risk and signs with patients and family members and should be aware of the burden of TD for patients and families. Up-to-date, evidence-based, expert guidance should be provided on using new medications to treat TD in patients with mood disorders and schizophrenia, including longer-term use. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on TD.

DISCLOSURE OF OFF-LABEL USAGE

Dr McEvoy has determined that, to the best of his knowledge, the following drugs are not approved by the US Food and Drug Administration for the treatment of tardive dyskinesia: lithium, botulinum toxin, amantadine, tetrabenazine, Ginkgo biloba, and clonazepam.

REVIEW PROCESS

The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.

ACKNOWLEDGMENT

This Brief Report is derived from the planning teleconference series "Early Recognition and Treatment of Tardive Dyskinesia in Patients with Mood Disorders and Schizophrenia," which was held in April, May, and June 2019 and supported by an educational grant from Neurocrine Biosciences, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.

FACULTY AFFILIATION

Joseph P. McEvoy, MD
Medical College of Georgia, Augusta

FINANCIAL DISCLOSURE

The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure is as follows:

Dr McEvoy has received grant/research support from Takeda, Alkermes, Boehringer Ingelheim, Teva, Neurocrine, and Otsuka; has received honoraria from Neurocrine; and is a member of the speaker/advisory boards for Merck, Neurocrine, and Alkermes.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

 

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

MOC APPROVAL STATEMENT 

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification DirectoryFDA-Approved Medications to Treat Tardive Dyskinesia has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC PART II CME ACTIVITY 

Psychiatry and Neurology

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this activity.

Register for free on our site to participate in this and many other free CME courses.